FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC

NCT04034459 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

109

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Bevacizumab
DRUG: Irinotecan
DRUG: Folinic acid
DRUG: Oxaliplatin
DRUG: 5-FU
DRUG: Cetuximab

Sponsor

Ludwig-Maximilians - University of Munich